School of Medicine


Showing 51-100 of 165 Results

  • Christopher Thomas Scott, PhD

    Christopher Thomas Scott, PhD

    Sr Research Scholar, Pediatrics - Center for Biomedical Ethics

    Current Research and Scholarly InterestsMy research focuses on the political, legal, ethical and economic impacts of stem cell research. Topics include: embryonic and adult stem cell research and clinical trials, stem cell banking, human-animal chimeras; cell and gamete donation; international perspectives of bioethics; global economic impacts; national and state regulatory policy, stem cell entrepreneurship, intellectual property and offshore stem cell transplants.

  • Talal Seddik

    Talal Seddik

    Clinical Associate Professor, Pediatrics - Infectious Diseases

    Current Research and Scholarly InterestsTalal Seddik is a member of the Collaborative Antiviral Study Group. He is the key site investigator at the Stanford site for the following multicenter studies:

    1) DMID 19-0026 Enterovirus Study
    Neonatal Enterovirus and Human Parechovirus Viral Sepsis: Natural History and Predictors of Morbidity and Mortality

    This study will be the first large, multi-state prospective assessment of the viral causes of neonatal sepsis conducted. The main reason for this research study is to get a better understanding of what causes neonatal viral sepsis and to assess the impact of the infection on the babies’ health. Viruses called enterovirus (EV) or human parechovirus (HPeV) are very common in the population and can cause neonatal viral sepsis. By gaining a better understanding of the condition, we hope this information can be used to guide diagnosis and treatment of babies with neonatal viral sepsis in the future.

    This study is actively enrolling subjects

    2) DMID 19-0005 Acute Flaccid Myelitis (AFM) Study
    A Prospective Study of Acute Flaccid Myelitis (AFM) to Define Natural History, Risk Factors and Pathogenetic Mechanisms

    Patients with suspected AFM (onset of flaccid limb weakness within the previous 30 days) are eligible to enroll in the study. Investigators will assess participants at four-time points within the first month of enrollment and will ask participants to return for additional follow up visits at 3 months, 7 months and 1 year. Neurologic improvements will be tracked over time, and samples will be collected and stored in a biorepository for use in future research studies. Household contacts, such as siblings, will be eligible to participate in the study as a control or comparison group.

    This study is actively enrolling subjects.

  • Seda Tierney

    Seda Tierney

    Professor of Pediatrics (Cardiology)

    Current Research and Scholarly InterestsAssessment of vascular health in children by non-invasive modalities

    Exercise interventions in children with congenital and acquired heart disease

    Use of telehealth to deliver interventions to children with congenital and acquired heart disease

    Parentally-acquired echocardiograms

    Quality Improvement in Pediatric Echocardiography

    Echocardiography and outcomes in congenital heart disease

  • Zachary M. Sellers, MD, PhD

    Zachary M. Sellers, MD, PhD

    Adjunct Professor, Pediatrics - Gastroenterology

    BioDr. Sellers is a pediatric physician-scientist and research and clinical development consultant. As a pediatric gastroenterologist and ion channel physiologist, Dr. Sellers' work in academia and pharma over the last 20 years has focused on improving the lives of individuals with complex and rare diseases through providing cutting-edge clinical care and advancing research and drug development. Dr. Sellers previously led a basic and translational research laboratory at Stanford, focused on epithelial ion transport and acid-base regulation using a variety of human and animal models. He is a firm believer in the exponential impact of team science and is adept working in multi-disciplinary and cross-functional teams. He seeks out strategic partnerships and opportunities that can leverage his expertise and leadership to advance innovative therapies for areas of high unmet need and to support the development of the next generation of physician-scientists. Dr. Sellers received his BS (Animal Physiology and Neuroscience) and BA (Japanese Studies) from the University of California. San Diego, his MD and PhD (Molecular and Integrative Physiology) from the University of Illinois at Urbana-Champaign, and was trained in Pediatrics and Pediatric Gastroenterology, Hepatology, and Nutrition at Stanford, where he was previously a faculty member and attending physician. He held multiple leadership positions at Stanford, including Associate Chief of Research in Gastroenterology, Director of the Stanford Children's Pancreas Program, Lead Gastroenterologist for the CF Program, Director of the CFTR Phenotyping and Theratyping Program, and Physician-Scientist Advisor for the Pediatrics Residency Program.

  • Ami J. Shah

    Ami J. Shah

    Clinical Professor, Pediatrics - Stem Cell Transplantation

    BioI joined Stanford University in 2015 as a Clinical Professor of Pediatrics in the Division of Hematology/ Oncology, Stem Cell Transplantation and Regenerative Medicine, having completed my training in Pediatric Hematology/ Oncology at Childrens Hospital Los Angeles. My areas of clinical expertise have been in the areas of transplantation for immune deficiencies and immune reconstitution post HSCT. I have been actively involved with the care and treatment of children with primary immune deficiencies and work with the Primary Immune Deficiencies Consortium (PIDTC). I am very interested in cellular therapies as a treatment modality for rare genetic diseases. I currently am the PI for several gene therapy trials at Stanford for various disorders including cerebral adrenoleukodystrophy (cALD), Sickle Cell Anemia, Thalassemia and Pyruvate Kinase Deficiency. My other main areas of research have been in studying the late effects of patients following stem cell transplantation, in specific the neurocognitive function post HSCT. I have been involved with several national committees addressing the late effects of HSCT within the ASBMT and COG.

    In addition to my research work in stem cell transplantation, I have been actively involved with mentorship and graduate medical education. I am currently the Program Director for the Hematology/ Oncology Fellowship and serve as a mentor through the Pediatric Mentoring Group.

  • Mona D. Shah, MD, MBA

    Mona D. Shah, MD, MBA

    Adjunct Clinical Associate Professor, Pediatrics - Hematology & Oncology

    BioDr. Mona Shah is a pediatric hematologist-oncologist, who earned her MD degree at the University of Maryland in 2001. She completed both her categorical pediatrics and global health residencies in 2004, followed by a pediatric hematology-oncology fellowship in 2007. She earned her MS in Clinical Investigation as part of the Clinical Scientist Training Program (CSTP) at Baylor College of Medicine in 2011, and more recently, completed an Executive MBA at Rice University Jones School of Business in 2018.

    Dr. Shah was an Associate Professor at Baylor College of Medicine (2007 - 2020) in both Pediatrics and Medicine, local site PI on a number of pediatric hemostasis/thrombosis clinical trials, and spent 10 years as an Associate Medical Director of Clinical Operations, Quality, and Safety at Texas Children’s Hospital, Houston, TX.

    Dr. Shah joined Genentech (a Member of the Roche Group)’s Rare Blood Disorders Franchise (Product Development - Oncology-Hematology) in February 2020, quickly advancing to Lead Medical Director, where she served as Medical Monitor for 2 Phase III Clinical Trials (crovalimab in atypical hemolytic uremic syndrome, aHUS). She was also engaged with the Renal Franchise (I2O) in developing crovalimab in Lupus Nephritis (Phase I & II Clinical Trials in development), and with Human Factors/Pediatric Formulations Working Group on autoinjector devices and oral formulations.

    After completing a rotation in Early Development Safety (EDS), she was promoted to Senior Medical Safety Director in Late Stage Product Development, and was appointed Safety Strategy Lead for giredestrant in early and metastatic breast, ovarian, and endometrial cancer global clinical trials. She has experience in innovative study designs (adaptive/multi-drug), with FDA/EMA pediatric investigational plans, and health authority interactions. In June 2023, she was appointed Pediatric Safety Lead, in collaboration with the iPODD Team, supporting safety for pediatric indications and devices, and serves as the Co-Chair of the Pediatric Safety Expert Group.

    Dr. Shah has kept and completed a bucket list since she was 7 years old (keeps growing): Running wild bouldering/rock climbing as a child in the Shenandoah/Blue Ridge Mountains, swimming with dolphins/piranhas in the Amazon, climbing inside a volcano caldera in Iceland, snorkeling the Great Barrier Reef ... have passport/will travel!

    Since July 2022, she has joined Stanford University School of Medicine, as an Adjunct Clinical Associate Professor in the Department of Pediatrics, Division of Hematology-Oncology, where she enjoys teaching MSII students, and at the bedside in the Lucille Packard Bass Center Hematology Clinic. Dr. Shah enjoys free time in her new home base near San Francisco, where she hosts her visiting parents, friends, and extended family.

  • Sejal Shah

    Sejal Shah

    Clinical Assistant Professor, Pediatrics - Endocrinology and Diabetes

    Current Research and Scholarly InterestsMy primary research interest is evaluating whether vitamin D supplementation can positively affect consequences of the metabolic syndrome in overweight and obese adolescents. Other research interests include evaluating the efficacy and biochemical profiles of various types of estrogen replacement in adolescent females.

  • Paul Sharek MD, MPH

    Paul Sharek MD, MPH

    Professor of Pediatrics (Hospital Medicine) at the Lucile Salter Packard Children's Hospital, Emeritus

    Current Research and Scholarly InterestsResearch interests centered on hospital based quality of care improvement, and in particular pediatric patient safety. Areas of recent interest include developing practical tools to more accurately identify adverse medical events and to establish national rates of these adverse events. Additional areas of interest focus on developing the processes and systems to decrease the frequency of adverse drug events and adverse medical events at Children's hospitals in North America

  • Seth Andrew Sharp

    Seth Andrew Sharp

    Postdoctoral Scholar, Endocrinology and Metabolism

    BioSeth is a Postdoctoral Fellow in the Translational Genomics of Diabetes lab located at Stanford Research Park under the supervision of Professor Anna Gloyn. Seth completed a B.E. in Applied Mathematics before studying a PhD at the University of Exeter with Dr Richard Oram where he researched the use of genetics to predict common autoimmune disorders. Seth studied at the Alan Turing Institute in London where he used machine learning and artificial intelligence methods to predict autoimmunity and has worked collaboratively to improve screening of Type 1 diabetes from birth. Seth's postdoctoral studies focus on using genetic, transcriptomic and epigenetic data to understand the mechanisms by which both Type 1 and Type 2 diabetes occur in the human pancreas. He is also interested in ways to quantify genetic risk such as polygenic risk scores and their application in both research and clinic.

  • Gary M. Shaw

    Gary M. Shaw

    NICU Nurses Professor and Professor (Research), by courtesy, of Epidemiology and Population Health and of Obstetrics and Gynecology (Maternal Fetal Medicine)

    Current Research and Scholarly InterestsPrimary research interests include 1) epidemiology of birth defects, 2) gene-environment approaches to perinatal outcomes, and 3) nutrition and reproductive outcomes.

  • Richard J. Shaw, M.D.

    Richard J. Shaw, M.D.

    Professor of Psychiatry and Behavioral Sciences (Child & Adolescent Psychiatry) &, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsPsychological issues in medically ill children.
    Medical posttraumatic stress disorder.
    Treatment adherence.
    Transplant psychiatry.
    Pediatric oncology.
    Forensic psychiatry.

  • Xinshu She

    Xinshu She

    Clinical Associate Professor, Pediatrics
    Clinical Associate Professor, Pediatrics - General Pediatrics

    Current Research and Scholarly InterestsMy current interests include global mental health promotion in underserved pediatric populations, including refugee health in US-Mexico borders, minority mental health in the US, and parental mental health in low-middle-income countries. I am also interested in physician wellness and Diversity and Inclusion.

  • Hiroyuki Shimada

    Hiroyuki Shimada

    Professor of Pathology and of Pediatrics

    BioHiroyuki Shimada, MD, PhD, FRCPA (Hon), is Professor of Pathology and of Pediatrics at the Stanford University Medical Center. He was born in Tokyo, Japan, and completed MD (1973) and PhD (1982) at the Yokohama City University School of Medicine, Yokohama, Japan, and also completed his pathology training at the Children's Hospital (now the Nationwide Children’s Hospital) and the Ohio State University, Columbus, Ohio, USA (1988). Before moving to the Stanford University in 2019, he was Professor of Pathology (Clinical Scholar) at the University of Southern California Keck School of Medicine and working at the Children’s Hospital Los Angeles.
    Dr. Shimada was Chair of the International Neuroblastoma Pathology Committee (1999-2017) and the founder of the International Neuroblastoma Pathology Classification (INPC). As Director of the COG (Children’s Oncology Group) Neuroblastoma Pathology Reference Laboratory (since 2001), he has been actively reviewing pathology samples of ~700 neuroblastoma cases per year from United States, Canada, Australia, and New Zealand. Pathology review results according to the INPC have been providing critical information for patient stratification and protocol assignment in the COG international neuroblastoma clinical trials.

  • Andrew Young Shin

    Andrew Young Shin

    Clinical Professor, Pediatrics - Cardiology

    Current Research and Scholarly InterestsSURF PROGRAM
    The SURF program is an innovative collaboration between LPCH, Stanford University Hospital and the Stanford School of Engineering. The program has focused on improving quality and safety of patient care, improving hospital operations and promoting clinical effectiveness utilizing contemporary technologies such as machine learning, mathematical optimization, simulation and a variety of statistical, probabilistic and computational tools. The program has 2 independent funding mechanism to primarily improve patient care/hospital operations and improve academics for faculty within the department of Pediatrics at LPCH.

    https://surf.stanford.edu/


    CLINICAL EFFECTIVENESS
    The Clinical Effectiveness (CE) Program is a funded program that aims to understand and improve unnecessary variation in healthcare delivery in order to optimize quality of care and reduce wasteful expenditures. The CE program has developed innovative programs such as Target Based Care, an award-winning intervention to reduce variation in hospital length of stay and currently a multi-center trial involving more than 20 hospitals in North America. In 2016, the CE program included the first CE fellowship program in a pediatric training program with 3 cycles of graduates. The CE program is supported by LPCH and a philanthropic gift by Susan Choe and Thomas Tobiason.

  • Ann Shue, MD

    Ann Shue, MD

    Clinical Assistant Professor, Ophthalmology
    Clinical Assistant Professor (By courtesy), Pediatrics

    Bio**Dr. Shue is taking new patients for glaucoma, cataracts, and adult strabismus.**

    Ann Shue, MD, is a Clinical Assistant Professor of Ophthalmology at Stanford University School of Medicine, where she specializes in glaucoma, pediatric ophthalmology, and adult strabismus, a unique combination of subspecializations practiced by few surgeons worldwide. She is a board-certified ophthalmologist who completed fellowships in glaucoma at Yale University and pediatric ophthalmology and adult strabismus at Duke University. She practices at the Stanford Byers Eye Institute and the Lucile Packard Children's Hospital.

    Dr. Shue loves seeing patients of all ages with eye problems big or small, including glaucoma due to any reason, glaucoma suspicion, family history of glaucoma, cataracts, strabismus (eye misalignment) or double vision from any cause, including after eye surgeries. She completed her ophthalmology residency at the University of Pittsburgh and an internal medicine internship at UCSF Fresno. She holds a medical degree from University of California, Irvine and an undergraduate degree in biology from Yale University.

    Dr. Shue is a member of the American Glaucoma Society, the American Association for Pediatric Ophthalmology and Strabismus, and the UK Paediatric Glaucoma Society. She is active in presenting at regional and national conferences. She is the author of several journal articles and recently wrote two textbook chapters on pediatric glaucoma and pediatric glaucoma surgery.

  • Eric Sibley, M.D., Ph.D.

    Eric Sibley, M.D., Ph.D.

    Professor of Pediatrics (Gastroenterology)

    Current Research and Scholarly InterestsMolecular Regulation of Intestinal Development and Maturation. We study transcriptional mechanisms regulating the spatial and temporal restriction of intestine-specific gene expression during gut development. Our approach is to characterize the function of gene-specific DNA cis elements and interacting nuclear proteins in cell culture and in transgenic animals. The goal is to relate the gene-specific control mechanisms to the broader pathways specifying acquisition of gut phenotypes.

  • Douglas Sidell, MD

    Douglas Sidell, MD

    Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsDr. Sidell's clinical interests include the management of children with voice and swallowing disorders, and congenital or acquired airway abnormalities. Examples of ongoing or upcoming prospective trials include an investigation into the utility of acid suppression in children with laryngomalacia, the management of vocal cord paralysis following cardiac surgery, and the management of type 1 laryngeal clefts in children.

  • Dawn H. Siegel, MD

    Dawn H. Siegel, MD

    Clinical Professor, Dermatology
    Clinical Professor (By courtesy), Pediatrics

    Current Research and Scholarly InterestsI'm dedicated to connecting patients with clinical research trials and contributing to research on specific skin conditions particularly hemangiomas, birthmarks, and PHACE syndrome. My research also aims to develop solutions to health disparities through improved access to pediatric dermatologists and treatments.

  • Norman H. Silverman

    Norman H. Silverman

    Honorary Faculty Emeritus, Pediatrics

    Current Research and Scholarly InterestsMy research interests center around cardiac ultrasound. I am currently working on several areas in the development of human cardiac ultrasound.

    These are fetal cardiac ultrasound. intraoperative and transesophageal ultrasound imaging in children, imaging potiential for ultrasound two and three dimensional modalities in children with congenital heart disease

  • Deepti Sinha

    Deepti Sinha

    Clinical Assistant Professor, Pediatrics - Pulmonary Medicine

    BioDr. Sinha is board certified in Pediatrics and Sleep Medicine. She completed medical school in Australia and general pediatric training in Australia and USA at Royal Children’s Hospital and University of Chicago at Illinois. Her sleep medicine fellowship was completed at Stanford Hospital. She enjoys working with children of all ages. She manages both behavioral and physiological sleep concerns.

  • Sidhartha Sinha

    Sidhartha Sinha

    Assistant Professor of Medicine (Gastroenterology and Hepatology)

    Current Research and Scholarly InterestsThere are two primary and overlapping emphases of my research, both of which are driven and united by needs-based innovation and translational potential:

    (1) Understanding the microenvironment of the inflamed versus normal gut in order to identify better therapeutic targets for people with immune-¬mediated GI disorders. Here, our investigations include understanding the influence and interactions of pharmacologic and dietary interventions on gut microbiome/metabolomic changes and the host immune response. In the context of providing patients with new understanding and solutions for their disease, I have led and advised on the design of both pilot and large clinical trials (including new FDA approved therapies) for anti-inflammatory therapies;

    (2) Applying novel approaches and technologies (including natural language processing, computer vision, and reinforcement learning) to identify and address unmet clinical needs. In this area we have ongoing and published efforts in my lab to validate and develop solutions to pressing clinical needs. We have developed/led new drug delivery technologies with a multidisciplinary team that have shown strong potential in ongoing human IBD clinical trials. My lab has utilized both supervised and unsupervised approaches to analyze social media discourse and unstructured data sets for identifying patient needs that are rarely addressed in clinical settings. We have gained insights into patient perceptions around preventative health interventions, such as health screening and diet, including the dearth of evidence-based dietary recommendations to treat IBD (despite strong patient desire for solutions in this domain).